This post was originally published on this site INmune Bio’s therapy candidate INB03 is well-tolerated and has shown signs of activity in patients with advanced cancers, according to preliminary findings from a Phase 1 clinical trial. The early results were revealed recently at the Cambridge Healthtech Institute’s 7th Annual Immuno-Oncology Summit, in the presentation, “Targeting Soluble…

This post was originally published on this site A Phase 1 trial is enrolling people with metastatic castration-resistant prostate cancer (mCRPC) to test Inovio Pharmaceutical‘s immunotherapy INO-5151 in combination with two other immunotherapies — Celldex’s CDX-301 and Bristol-Myers Squibb’s Opdivo (nivolumab). The PORTER study (NCT03835533) will include 45 patients who were previously treated with second-generation androgen receptor inhibitors…

This post was originally published on this site Hospitals that perform many ovarian cancer surgeries tend to have better treatment outcomes in terms of mortality, a study suggests. But restricting this surgery to only high-volume hospitals would greatly limit treatment availability while only meagerly increasing survival rates, the researchers say. The study, published in the…

This post was originally published on this site People with monoclonal gammopathy of undetermined significance (MGUS) placed at low- or intermediate-risk of progression to multiple myeloma can develop that cancer within five years, a study of blood serum immune markers reports. This finding warrants annual blood testing for these people, researchers wrote in the study…

This post was originally published on this site An educational conference for people with sarcoidosis and those close to them will be held at the University of Cincinnati this Saturday, featuring doctors with expertise in this disease, presentations, and a question-and-answer session. The Aug. 24 event at the Ohio university’s Kresge Auditorium runs from 10:00 a.m. to 4:00…

This post was originally published on this site The Phase 2 trial evaluating Sellas Life Sciences‘ cancer vaccine NeuVax as a treatment for women with early stage HER2-positive ductal carcinoma in situ (DCIS), a non-invasive breast cancer, has completed patient enrollment. The vaccine is made of Sellas’ nelipepimut-S, the active ingredient that educates the immune system…

This post was originally published on this site A Phase 1/2a trial testing the advanced solid tumor treatment candidate IMX-110 in Australia has been cleared by the U.S. Food and Drug Administration to enroll participants in the United States. Immix is now selecting the medical centers that will participate in the trial. Australia is the…

This post was originally published on this site Evomela, an injectable formulation of melphalan, is now available in China as a high-dose conditioning therapy for people with multiple myeloma who will undergo a stem cell transplant, CASI Pharmaceuticals, its maker, announced. The product is also approved as a palliative treatment for patients who cannot take oral medicines.…

This post was originally published on this site The European Commission (EC) has expanded the use of Imbruvica (ibrutinib) to cover combinations with Gazyva (obinutuzumab) for previously untreated adults with chronic lymphocytic leukemia (CLL), and with MabThera (rituximab) for adults with Waldenström’s macroglobulinemia (WM). This decision follows a recent positive opinion from the European Medicines Agency’s…

This post was originally published on this site Cancer has a way of isolating us. Friends and family can be supportive, but sometimes they don’t understand what you’re going through. I have found that it helps to think of myself as one part of a larger community. In my 11-plus years as a follicular lymphoma…

This post was originally published on this site ADXS-NEO, an investigational cancer immunotherapy, induced an immune response against 90% of all cancer targets in a patient with metastatic microsatellite stable colorectal cancer (MSS-CRC), data from an ongoing Phase 1 trial show. ADXS-NEO, jointly developed by Advaxis and Amgen, is a new type of personalized cancer…

This post was originally published on this site Immunotep has completed patient enrollment for its Phase 2b trial evaluating eftilagimod alpha (IMP321) — an investigational therapy that stimulates the immune system to fight cancer — in combination with standard chemotherapy for women with hormone receptor (HR)-positive and HER2-negative advanced breast cancer. Combining active immunotherapy with…